Download MendeleyReversible, Orally Bioavailable Small-Molecule Inhibitors Occupy the Substrate Tunnel of the Thioesterase Domain of Fatty Acid Synthase.
Fromm, J., Aleshin, A., Lambert, L.J., De Backer, L.J.S., Ganji, S.R., Mattmann, M.E., Limpert, A.S., Gosalia, P., Wimer, C.D., Layng, F.I., Celeridad, M., Ardecky, R., Teriete, P., Scott, D.A., Hedrick, M.P., Smith, J.W., Sheffler, D.J., Cosford, N.D.P.(2026) bioRxiv
- PubMed: 42926451 Search on PubMedSearch on PubMed Central
- DOI: https://doi.org/10.64898/2026.10.01.756096
- Primary Citation Related Structures:
9ZLX - PubMed Abstract:
Fatty acid synthase (FASN) is the sole enzyme capable of lipogenesis in cells and is upregulated in many cancers. Herein we report the discovery and development of SBP-5917 ( 78S ), a novel, reversible, small-molecule probe which targets the thioesterase (TE) domain of FASN. SBP-5917 and other compounds in the series possess IC 50 < 1 µM and < 5 µM for inhibiting recombinantly purified FASN-TE and cellular FASN respectively. Co-crystal structures of our inhibitors bound to the FASN-TE domain show that they are positioned in the substrate tunnel of the enzyme. Biochemical and biophysical analyses quantify the strength of compound binding and demonstrate their selectivity for FASN-TE. Preliminary pharmacokinetic studies indicate promising in vivo potency for many of the compounds in the series. SBP-5917 is the first structurally validated, reversible inhibitor of FASN-TE with demonstrated cellular target engagement and can serve as a chemical probe to investigate FASN as a therapeutic target.
